Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.67 USD | +2.73% | +5.47% | +43.31% |
Jun. 06 | Transcript : Addex Therapeutics Ltd, Q1 2024 Earnings Call, Jun 06, 2024 | |
Jun. 06 | Addex Therapeutics' Q1 Net Loss Widens; Revenue Down | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As estimated by analysts, this group is among those businesses with the lowest growth prospects.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- One of the major weak points of the company is its financial situation.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- Most analysts recommend that the stock should be sold or reduced.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+43.31% | 6.59M | - | ||
+18.97% | 45.34B | B- | ||
+41.98% | 40.42B | A | ||
-10.06% | 37.92B | B | ||
+31.15% | 31.75B | B | ||
-7.79% | 27.71B | C | ||
+13.32% | 26.52B | B- | ||
+43.05% | 13.96B | B+ | ||
+31.28% | 12.44B | C+ | ||
-7.41% | 11.26B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ADXN Stock
- ADXN Stock
- Ratings Addex Therapeutics Ltd